Nasaruplase beta - Microbix

Drug Profile

Nasaruplase beta - Microbix

Alternative Names: A-74187; ABT 187; MRX-515; PROLYSE; r-ProUK

Latest Information Update: 29 Aug 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Class Anti-ischaemics; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Peripheral vascular disorders; Stroke

Most Recent Events

  • 31 Dec 2009 Discontinued - Phase-III for Stroke in Canada (IV)
  • 31 Dec 2009 Discontinued - Phase-III for Stroke in USA (IV)
  • 24 Sep 2008 Microbix Biosystem Inc acquires urokinase protfolio from ImaRx Therapeutics Inc ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top